UPSTAGED RISK FROM THE REVISED TO THE MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM PREDICTS ADVERSE OUTCOMES IN MYELODYSPLASTIC SYNDROMES

EHA Library, Alexandre Bazinet, 4160707

TP53 MUTATIONS DISTINGUISH A CLASS OF HIGHLY HOMOGENOUS MYELOID NEOPLASMS WITHIN MDS AND AML IN THE CONTEXT OF COMPLEX KARYOTYPE

EHA Library, Ye Yang, 4160708

ASSESSING AVAILABLE RISK SCORES FOR DISEASE PROGRESSION AND SURVIVAL IN CCUS: A SINGLE-INSTITUTION STUDY

EHA Library, Aref Al-Kali, 4160709

SPECTRUM, PREVALENCE AND CLINICAL CORRELATES OF PPM1D MUTATIONS IN PATIENTS WITH THERAPY RELATED CLONAL HEMATOPOIESIS AND CLONAL CYTOPENIAS

EHA Library, Talha Badar, 4160710

PHASE 2 RANDOMISED TRIAL, REPURPOSING DANAZOL AND VBAP IN LOW RISK MYELODYSPLASTIC SYNDROME: REPAIR-MDS

EHA Library, Manoj Raghavan, 4160711

A PHASE I OPEN LABEL STUDY OF FOSTAMATINIB, A SYK INHIBITOR, IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Jennifer Croden, 4160712

PHASE I/II TRIAL OF AZACITIDINE AND VENETOCLAX IN PREVIOUSLY UNTREATED AND HYPOMETHYLATING AGENT FAILURE MYELODYSPLASTIC SYNDROME: AN INTERIM EFFICACY ANALYSIS

EHA Library, Ian Bouligny, 4160713

HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH IMETELSTAT IN THE IMERGE TRIAL

EHA Library, María Díez Campelo, 4160714

OUTCOMES WITH IMETELSTAT BY SERUM ERYTHROPOIETIN LEVELS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES WHO WERE TREATMENT NAIVE OR WHO HAD PRIOR TREATMENT WITH ERYTHROPOIESIS-STIMULATING AGENTS

EHA Library, Rami S. Komrokji, 4160715

VALIDATION OF MASP-3 AS A NOVEL PROXIMAL TARGET FOR COMPLEMENT-MEDIATED DISEASES: LEARNINGS FROM NONCLINICAL AND CLINICAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) STUDIES

EHA Library, W. Jason Cummings, 4160716

THERAPEUTIC INTERVENTION IN BONE MARROW FAILURES: TARGETING NUCLEOLAR AND RIBOSOME STRESS INDUCED BY HNRNPK OVEREXPRESSION

EHA Library, Miguel Gallardo, 4160717

METABOLIC DYSREGULATION IN ERCC6L2 DISEASE: IMPLICATIONS FOR ERYTHROPOIESIS THROUGH GLUTAMINE, GLUTATHIONE, AND FERROPTOSIS PATHWAYS

EHA Library, Ilse Kaaja, 4160718

SOMATIC PRE-MALIGNANT CLONES IN THE ORAL MUCOSA OF FANCONI ANEMIA PATIENTS, WITH AND WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Tamar Berger, 4160719

NOVEL TOOLS TO DISCOVER THE CELLULAR SOURCES OF GENOTOXIC FORMALDEHYDE THAT DRIVES FANCONI ANEMIA

EHA Library, Brandon James, 4160720

BOTH RARE PNH CELLS AND MINOR PNH CLONES SHOULD BE CONSIDERED AS GENUINE PNH CLONES: INSIGHTS FROM ANALYSIS OF THE 5-YEAR FRENCH NATION-WIDE MULTICENTER OBSERVATIONAL STUDY

EHA Library, Orianne Wagner-Ballon, 4160721

THE ROLE OF CD8+CD28-REGULATORY T CELLS IN ACQUIRED APLASTIC ANEMIA

EHA Library, Meili Ge, 4160722

THE SUBGROUP OF APLASTIC ANEMIA PATIENTS IS CHARACTERIZED BY IMPAIRED MESENCHYMAL STROMAL CELLS PROLIFERATION AND ADIPOGENIC DIFFERENTIATION

EHA Library, Alena Dorofeeva, 4160723

ACCURATE QUANTIFICATION OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA CLONE IN NEUTROPHILS: ADDED VALUE OF ANTI-CD16 ANTIBODY IN ELIMINATING EOSINOPHIL CONTAMINATION

EHA Library, Bouchra BADAOUI, 4160724

ANALYSIS OF THE RECOVERY OF IMMUNE STATUS IN THE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AFTER TREATMENT WITH COMPLEMENT C5 INHIBITOR

EHA Library, Rong Fu, 4160725

HETROMBOPAG COMBINED WITH CYCLOSPORINE A AS FIRST-LINE TREATMENT IN PATIENTS WITH NON-SEVERE APLASTIC ANEMIA: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY

EHA Library, Xin Zhao, 4160726

DANICOPAN ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS STRATIFIED BY BONE MARROW FAILURE HISTORY

EHA Library, Morag Griffin, 4160727

BUSULFAN, LOW DOSE CYCLOPHOSPHAMIDE, AND FLUDARABINE VERSUS BUSULFAN PLUS STANDARD-DOSE CYCLOPHOSPHAMIDE CONDITIONING REGIMEN IN HAPLOIDENTICAL CELL TRANSPLANTATION FOR PATIENTS WITH ACQUIRED APLASTIC ANEMIA: A PROPENSITY SCORE MATCHED CONTROLLED STUDY.

EHA Library, Fan Lin, 4160728

EVALUATING THE SAFETY AND EFFICACY OF MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH CHRONIC NEUTROPENIC DISORDERS: RESULTS FROM THE PHASE 2 STUDY

EHA Library, Julia Warren, 4160729

CLINICAL AND GENETIC CHARACTERISTICS OF A LARGE COHORT OF PEDIATRIC PATIENTS WITH SHWACHMAN-DIAMOND SYNDROME (SDS)

EHA Library, Ekaterina Deordieva, 4160730

CYCLOPHOSPHAMIDE COMBINED WITH STANDARD IMMUNOSUPPRESSIVE THERAPY IMPROVES EARLY RESPONSE RATES IN SEVERE APLASTIC ANEMIA: A PHASE II CLINICAL TRIAL

EHA Library, Hong Pan, 4160731

THE SURVIVAL ADVANTAGE OF REDUCED-TOXICITY CONDITIONING WITH BUSULFAN/FLUDARABINE/LOW-DOSE CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA PATIENTS WITH PRE-TRANSPLANT COMORBIDITIES.

EHA Library, Fan Lin, 4160732

SPECTRUM AND PREVALENCE OF NON-HEMATOLOGICAL MALIGNANCIES IN PATIENTS WITH TELOMERE BIOLOGY DISORDERS

EHA Library, Madeline Franke, 4160733

IMMUNE-DRIVEN SELECTION AND FREQUENT DETECTION OF PNH CLONES IN POST-CAR-T THERAPY HEMATOPOIETIC FAILURE

EHA Library, Yuki Nukii, 4160734

COMPARISON OF OF HETROMBOPAG VERSUS ELTROMBOPAG COMBINED WITH ANTI-THYMOCYTE GLOBULIN AND CYCLOSPORINE A AS FIRST-LINE THERAPY FOR SEVERE APLASTIC ANEMIA: SIMILAR EFFICACY AND SAFETY

EHA Library, Jingnan Sun, 4160735

DUAL PLATFORM GENOMIC TESTING FROM DIRECT SKIN BIOPSY FOR DETECTION OF GERMLINE PREDISPOSITION IN BONE MARROW FAILURE AND HEMATOLOGIC MALIGNANCY

EHA Library, Enrico Attardi, 4160736

A BENEFIT ASSESSMENT OF PEGCETACOPLAN DOSE INCREASE IN THE PHASE 3 PEGASUS TRIAL OF PNH PATIENTS WITH DIFFICULT-TO-CONTROL DISEASE

EHA Library, Morag Griffin, 4160737

IMPACT OF FRONT-LINE ALLOGENEIC HSCT OR IMMUNOSUPPRESSIVE THERAPY ON SURVIVAL IN APLASTIC ANEMIA PATIENTS

EHA Library, Alfadil Haroon, 4160738

MOLECULAR AND CLINICAL FEATURES OF ACQUIRED APLASTIC ANEMIA WITH DDX41 MUTATIONS

EHA Library, Xin Zhao, 4160739

BENEFIT OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IRRESPECTIVE OF BASELINE TRANSFUSION STATUS

EHA Library, Britta Höchsmann, 4160740

THE STOCKHOLM NEUTROPENIA STUDY - COMPARISONS OF PATIENTS WITH IDIOPATHIC OR AUTOIMMUNE NEUTROPENIAS

EHA Library, Henric Lindqvist, 4160741

LONG-TERM OUTCOMES OF ELTROMBOPAG TREATMENT IN FANCONI ANEMIA PATIENTS WITH BONE MARROW DYSFUNCTION: EXTENDED FOLLOW-UP FROM THE FANCREV TRIAL

EHA Library, Guzmán López de Hontanar Torres, 4160742

CHARACTERISTICS OF HEMATOLOGICAL DISORDERS IN SHORT TELOMERE SYNDROMES

EHA Library, Inés Zugasti, 4160743

MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, ALLOWS FOR GRANULOCYTE-COLONY STIMULATING FACTOR DOSE DE-ESCALATION IN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA AND CONGENITAL NEUTROPENIA

EHA Library, Julia Warren, 4160744

ANELLOVIRUS-ASSOCIATED SUBOPTIMAL HEMATOLOGICAL RECOVERY IN SEVERE APLASTIC ANEMIA AFTER IMMUNOSUPPRESSIVE THERAPY

EHA Library, Guangsheng He, 4160745

PROPHYLAXIS AND MANAGEMENT OF THROMBOEMBOLISM IN PNH PATIENTS: AN ITALIAN SURVEY

EHA Library, Anna Paola Iori, 4160746

NEW CONSENSUS RISK DEFINITION PREDICTS OUTCOMES WITH DARATUMUMAB-BASED QUADRUPLET REGIMENS FOR MULTIPLE MYELOMA

EHA Library, Kylee Maclachlan, 4160747

SELECTIVE DEPLETION OF B-CELL LINEAGE SUBSETS DURING TREATMENT WITH ANTI-BCMA VS ANTI-GPRC5D BISPECIFIC ANTIBODIES (BSABS) UNDERLIES DIFFERENT RISK OF INFECTIONS IN PATIENTS WITH MULTIPLE MYELOMA (MM)

EHA Library, Tomas Jelinek, 4160748

MEZIGDOMIDE (MEZI) IN NOVEL COMBINATIONS EFFECTIVELY REACTIVATES IMMUNE SYSTEM IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) INCLUDING THOSE AFTER T-CELL-REDIRECTING THERAPIES

EHA Library, Luciano J. Costa, 4160749

MOLECULAR INSIGHTS INTO MULTIPLE MYELOMA BONE DISEASE: SINGLE-NUCLEUS RNA-SEQ ANALYSIS OF OSTEOCLAST DIFFERENTIATION

EHA Library, Melika Bakharzi, 4160750

ZMYND8 READS H3K36ME2 TO ACTIVATE CEBPE TRANSCRIPTION AND SUPPRESS MULTIPLE MYELOMA PROGRESSION THROUGH THE INHIBITION OF ADAPTIVE UPR PATHWAYS

EHA Library, Bing Chen, 4160751

CAR-T CELL BASED ON STEM CELL-LIKE MEMORY T CELL ENHANCES ANTI-TUMOUR EFFECT ON MULTIPLE MYELOMA

EHA Library, Zhaoyun Liu, 4160752

CCR4 MODULATES MALIGNANT PROGRESSION OF MULTIPLE MYELOMA VIA PI3K/AKT/MTOR SIGNALING AXIS: MECHANISTIC INSIGHTS AND TARGETED THERAPEUTIC STRATEGY

EHA Library, Yonghuai Feng, 4160753

A NOVEL PEPTIDE-BASED PROTAC SELECTIVELY TARGETING NUCLEUS EXPORT PROTEIN XPO1 FOR MULTIPLE MYELOMA THERAPY

EHA Library, Yi Liu, 4160754

HP-001, AN ORAL IKZF 1/3 MOLECULAR GLUE, DEMONSTRATED SUPERIOR DEGRADATION POTENCY AND SPECIFITY IN THE PRE-CLINICAL MODEL

EHA Library, Dihuang Wang, 4160755

CREB1 GLOBALLY REGULATES OXIDATIVE STRESS AND PROTEOTOXICITY IN MULTIPLE MYELOMA

EHA Library, Francesca Cottini, 4160756

THE MECHANISM OF EXOSOMAL CIRC-G042080 PROMOTING MYELOMA BONE DISEASE THROUGH MIR-6791-3P/HDAC4/RANKL AXIS

EHA Library, Xing Cui, 4160757

IMMUNOMMAP: INSIGHTS INTO IMMUNE AND GENOMIC ALTERATIONS UNDERLYING THE RESISTANCE TO BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA BY FULL SPECTRUM CYTOMETRY AND EXOME SEQUENCING

EHA Library, Daniel Bilek, 4160758

EPIGENETIC DRIVERS OF IMMUNOTHERAPY RESISTANCE IN MULTIPLE MYELOMA: ADVANCED MULTI-OMIC PROFILING IDENTIFIES BCMA AND FCRL5 SILENCING VIA LONG-RANGE DNA HYPERMETHYLATION

EHA Library, Larissa Haertle, 4160759

BELANTAMAB MAFODOTIN TREATMENT TRIGGERS IMMUNOLOGIC AND INFLAMMATORY CELL DEATH IN MYELOMA, WITH IMPLICATIONS FOR THE TUMOUR MICROENVIRONMENT AND DURATION OF RESPONSE.

EHA Library, Edmund Watson, 4160760

MECHANISM OF BUTYRATE-REMODELED FATTY ACID OXIDATION IN NK CELLS IN THE TREATMENT OF MULTIPLE MYELOMA WITH DARATUMUMAB

EHA Library, Tingting Li, 4160761

ROLE AND MECHANISM OF PIM-2 KINASE INHIBITOR-INDUCED IMMUNOGENIC CELL DEATH IN MULTIPLE MYELOMA

EHA Library, Hongli Shen, 4160762

ACQUIRED PYRIDOXAL PHOSPHATE (VITAMIN B6) DEFICIENCY AS MECHANISM FOR NEUROPATHY IN POEMS SYNDROME

EHA Library, Oliver Tomkins, 4160763

INCREASING TUMOR DENSITIES ARE ASSOCIATED WITH REMODELING OF THE BONE MARROW MYELOID AND STROMAL MICROENVIRONMENT IN NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Marnix Koops, 4160764

COMPLEMENT AND AMYLOID SIGNATURE PROTEIN UPREGULATION IN POST- TREATMENT AL AMYLOID PROTEOMES PROVIDES NOVEL INSIGHTS INTO DISEASE BIOLOGY

EHA Library, Matthew Rees, 4160765

THE IMMUNOMODULATORY EFFECTS OF DARATUMUMAB-BASED THERAPY ON FUNCTIONAL HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA (FHRMM) PATIENTS ENROLLED IN THE MYDRUG OBSERVATIONAL TRIAL

EHA Library, Chaitanya Acharya, 4160766

IMAGE-BASED EX-VIVO IMMUNOTHERAPY SCREENING ASSAY PREDICTS RESPONSE TO BISPECIFIC T CELL ENGAGERS IN MULTIPLE MYELOMA PATIENTS

EHA Library, Frederik Herzberg, 4160767

DIRECT TARGETING ONCOGENIC RAS ON LEUKEMIC CELLS WITH BI-SPECIFIC PCC ANTIBODIES NOT RESTRICTED TO THE HLA SYSTEM

EHA Library, Thomas Bumm, 4160768

PAEONIFLORIN INHIBITS THE ANGIOGENESIS OF MULTIPLE MYELOMA VIA DECREASING MEF2A LEVEL TO DOWNREGULATE THE EXPRESSION OF EXOSOMAL LNCRNA MALAT1

EHA Library, Xing Cui, 4160769

IDENTIFICATION OF TRANSLOCATION-INDUCED ENHANCER HIJACKING IN MULTIPLE MYELOMA BY TRANSFINDER

EHA Library, Jin Lu, 4160770

DI-(2-ETHYLHEXYL) PHTHALATE (DEHP) AND ITS METABOLITE PROMOTE MULTIPLE MYELOMA PROGRESSION AND BORTEZOMIB RESISTANCE

EHA Library, Wenxia Li, 4160771

GENOMIC LANDSCAPE OF PARA-SKELETAL AND EXTRAMEDULLARY PLASMACYTOMAS IN MULTIPLE MYELOMA PATIENTS

EHA Library, Martin Stork, 4160772

IMPAIRED BONE MARROW AND CIRCULATING γΔ T CELLS WERE LINKED TO AN INCREASED RISK OF PROGRESSING FROM PRE-MALIGNANT PLASMA CELL CONDITIONS TO SYMPTOMATIC MULTIPLE MYELOMA

EHA Library, Anna Maria Corsale, 4160773

DEFINING A NOVEL CYTOKINE COMBINATION TO OPTIMIZE IN VITRO CULTURE CONDITIONS FOR PRIMARY MULTIPLE MYELOMA PATIENT CELLS

EHA Library, Ariene Cabantog, 4160774

THE BIOLOGICAL RELEVANCE OF UPREGULATED NONO PROTEIN IN MULTIPLE MYELOMA THROUGH THE REGULATION OF CELL CYCLE PROGRESSION AND DRUG TREATMENT RESPONSE

EHA Library, Giuseppina Fabbiano, 4160775

TARGETING MAT2A ALTERS THE METHYLATION LANDSCAPE AND DNA DAMAGE RESPONSE IN MULTIPLE MYELOMA, REVEALING NOVEL COMBINATION STRATEGIES.

EHA Library, Lien Van Hemelrijck, 4160776

THE STORY OF THE GUT MICROBIOME AND MULTIPLE MYELOMA: THE CHICKEN OR THE EGG?

EHA Library, Sylvia Faict, 4160777

PYGO2 IS OVEREXPRESSED BY CD138+ CELLS IN MULTIPLE MYELOMA PATIENTS WITH 1Q AMPLIFICATION IRRESPECTIVE OF CYTOGENETIC HETEROGENEITY: A NEW POSSIBLE DRUGGABLE TARGET

EHA Library, Nicolas Thomas Iannozzi, 4160778

PAEONIFLORIN ATTENUATES MOUSE MYELOMA BONE DISEASE BY REDUCING ERK 1 LEVELS IN THE EXOSOMES OF MULTIPLE MYELOMA CELLS

EHA Library, Xing Cui, 4160779

PERCENTAGE OF ACTIVATED CD4+ T LYMPHOCYTES AMONG T LYMPHOCYTES PREDICT HEMATOLOGIC RESPONSE TO IMMUNOSUPPRESSIVE THERAPY IN APLASTIC ANEMIA

EHA Library, Youzhen Xiong, 4160780

IN SILICO-IDENTIFIED PUTATIVE INHIBITORS OF PARASPECKLE ASSEMBLY INDUCE CELL DEATH BY APOPTOSIS IN MULTIPLE MYELOMA CELLS AND LEAD TO THE ACTIVATION OF THE CGAS/STING PATHWAY.

EHA Library, Valentina Traini, 4160781

EXPLORING THE ROLE OF NONO IN TRANSCRIPTIONAL REGULATION OF CELLULAR PATHWAYS IN MULTIPLE MYELOMA: INSIGHTS INTO ITS PARASPECKLE-DEPENDENT AND INDEPENDENT REGULATORY MECHANISMS

EHA Library, Elisa Taiana, 4160782

PREDICTIVE MODEL FOR NON-INVASIVE DIAGNOSIS AND PROGNOSIS OF MULTIPLE MYELOMA BY INTEGRATING LIQUID BIOPSY BIOMARKERS

EHA Library, Ana C. Queirós, 4160783

MYELOMA-ASSOCIATED MACROPHAGES INDUCE DRUG-RESISTANCE THROUGH SREBP1-DEPENDENT LIPID METABOLIC DYSREGULATION IN MULTIPLE MYELOMA

EHA Library, Xing Guo, 4160784

RISK RECLASSIFICATION IN MULTIPLE MYELOMA: ASSESSING THE SHIFT FROM MSMART V3.0 TO V4.0

EHA Library, Jorge Hurtado Martinez, 4160785

UPDATED RESULTS OF A PHASE I OPEN-LABEL SINGLE-ARM STUDY OF DUAL TARGETING BCMA AND CD19 FASTCAR-T (GC012F/AZD0120) AS FIRST-LINE THERAPY FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED HIGH-RISK MULTIPLE MYELOMA

EHA Library, Juan Du, 4160786

DARATUMUMAB + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN THE PHASE 3 PERSEUS TRIAL

EHA Library, Philippe Moreau, 4160787

ELEVATED PROPORTIONS OF RESIDUAL BONE MARROW CLONAL PLASMA CELLS IN S-PHASE PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IS ASSOCIATED WITH HIGH RISK OF EARLIER RELAPSE IN MULTIPLE MYELOMA PATIENTS

EHA Library, Tamer Hellou, 4160788

ISATUXIMAB WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOLLOWED BY ISATUXIMAB AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: A PHASE 2 STUDY BY THE GREEK MYELOMA STUDY GROUP

EHA Library, Evangelos Terpos, 4160789

LINVOSELTAMAB + BORTEZOMIB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL RESULTS FROM THE LINKER-MM2 TRIAL

EHA Library, Paula Rodríguez-Otero, 4160791

NARLUMOSBART COMPARED WITH DENOSUMAB IN THE TREATMENT OF BONE DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: A MULTICENTER, RANDOMIZED, CONTROLLED, NON-INFERIORITY STUDY

EHA Library, Fei Li, 4160792

IMPACT OF MASS SPECTROMETRY ON THE EVALUATION OF MAINTENANCE TREATMENT IN PATIENTS WITH MYELOMA ENROLLED IN THE GEM2014MAIN TRIAL: INSIGHTS INTO TREATMENT RESPONSE AND DISEASE PROGRESSION

EHA Library, Noemi Puig, 4160794

DELETION 17P, AND IGH HIGH RISK TRANSLOCATIONS ALONG WITH CHROMOSOME 1 ABNORMALITIES ARE THE STRONGEST SURVIVAL PREDICTORS IN MULTIPLE MYELOMA: A REAL-WORLD VALIDATION BY THE GREEK MYELOMA STUDY GROUP

EHA Library, Eirini Katodritou, 4160795

BCMA-TARGETING T-CELL REDIRECTING BISPECIFIC ANTIBODY THERAPY POST-GPRC5D-DIRECTED BISPECIFIC ANTIBODY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA. (IFM 2024-13 BCMA POST-GPRC5D)

EHA Library, Cyrille Hulin, 4160796

POSITRON EMISSION TOMOGRAPHY WITH COMPUTED TOMOGRAPHY AND MINIMAL RESIDUAL DISEASE FOR EFFICACY ASSESSMENT IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: IMROZ ANALYSIS

EHA Library, Elena Zamagni, 4160797

CILTACABTAGENE AUTOLEUCEL VERSUS STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: CARTITUDE-4 SURVIVAL SUBGROUP ANALYSES

EHA Library, Yael Cohen, 4160798

EFFICACY AND SAFETY OF FRONTLINE ALTERNATING BORTEZOMIB-BASED REGIMENS PLUS DARATUMUMAB IN PRIMARY PLASMA CELL LEUKEMIA: INTERIM RESULTS OF EUMELEIA PHASE 2 TRIAL BY THE GREEK MYELOMA STUDY GROUP.

EHA Library, Eirini Katodritou, 4160799

EFFICACY OF RADIOTHERAPY AND ROLE OF ADJUNCTIVE IMMUNOCHEMOTHERAPY IN POEMS SYNDROME WITH SOLITARY PLASMACYTOMA

EHA Library, Wai Nga Grace Lau, 4160800

EFFICACY AND SAFETY OF ISATUXIMAB SUBCUTANEOUS (SC) PLUS CARFILZOMIB AND DEXAMETHASONE (ISA-KD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS OF THE PHASE 2 STUDY IZALCO

EHA Library, Gurdeep Parmar, 4160801

MEZIGDOMIDE (MEZI) IN NOVEL COMBINATIONS FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM THE CA057-003 TRIAL

EHA Library, Fredrik Schjesvold, 4160802

ABSOLUTE LYMPHOCYTE COUNT AS A KEY BIOMARKER FOR MONITORING SAFETY AFTER CILTACABTAGENE AUTOLEUCEL

EHA Library, Yi Lin, 4160803

SIMULTANEOUS WHOLE-BODY MULTI-PARAMETRIC 2-[18F]FDG-PET/MRI IN SMOLDERING MULTIPLE MYELOMA ASSESSMENT : DIAGNOSTIC AND PROGNOSTIC IMPACT

EHA Library, Bastien Jamet, 4160804

DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF TRANSPLANT-INELIGIBLE PATIENTS IN THE PHASE 3 CEPHEUS STUDY

EHA Library, Thierry Facon, 4160805

AUTOLOGOUS B CELL MATURATION ANTIGEN (BCMA) AND CD19 DUAL TARGETING FASTCAR-T CELLS (GC012F/AZD0120) AS FIRST-LINE THERAPY FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Juan Du, 4160806

BCMA-TARGETING BISPECIFIC T-CELL ENGAGERS WITH PROPHYLACTIC TOCILIZUMAB USE ARE SAFE AND INDUCE DEEP AND RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY STAGE 3 AL AMYLOIDOSIS

EHA Library, Romain Gounot, 4160807

ENHANCED REAL-WORLD OUTCOMES IN MULTIPLE MYELOMA FOLLOWING IMPLEMENTATION OF ALCYONE, CASSIOPEIA, MAIA, AND PERSEUS PROTOCOLS IN SWEDISH NATIONAL GUIDELINES: DATA FROM THE SWEDISH MYELOMA REGISTRY (2008-2024)

EHA Library, Cecilie Hveding Blimark, 4160808